Publicaciones
-
Fernandez-Plana J; Pericay C; Quintero G; Alonso V; Salud A; Mendez M; Salgado M; Saigi E; Cirera L
Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)
Bmc Cancer 14 865-865. .
-
Fernandez-Martos C; Brown G; Estevan R; Salud A; Montagut C; Maurel J; Safont MJ; Aparicio J; Feliu J; Vera R; Alonso V; Gallego J; Martin M; Pera M; Sierra E; Serra J; Delgado S; Roig JV; Santos J; Pericay C
Preoperative Chemotherapy in Patients With Intermediate-Risk Rectal Adenocarcinoma Selected by High-Resolution Magnetic Resonance Imaging: The GEMCAD 0801 Phase II Multicenter Trial
Oncologist 19 1042-1043. .
-
Gomez-Martín, C.; Lopez-Rios, F.; Aparicio, J.; Barriuso, J.; García-Carbonero, R.; Pazo, R.; Rivera, F.; Salgado, M.; Salud, A.; Vázquez-Sequeiros, E.; Lordick, F.
A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond
CANCER LETTERS 351 30-40. .
-
Feliu J; Salud A; Safont MJ; García-Girón C; Aparicio J; Vera R; Serra O; Casado E; Jorge M; Escudero P; Bosch C; Bohn U; Pérez-Carrión R; Carmona A; Martínez-Marín V; Maurel J
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study
BRITISH JOURNAL OF CANCER 111 241-248. .
-
Novell, A; Martinez-Alonso, M; Mira, M; Tarragona, J; Salud, A; Matias-Guiu, X
Prognostic value of c-FLIPL/s, HIF-1 alpha, and NF-kappa beta in stage II and III rectal cancer
VIRCHOWS ARCHIV 464 645-654. .
-
Nabal M; Palomar C; Juvero MT; Taberner MT; León M; Salud A
Sedación paliativa: situación actual y áreas de mejora.
Revista de calidad asistencial : organo de la Sociedad Española de Calidad Asistencial 29 104-111. .
-
Gomez-Martin C; Plaza JC; Pazo-Cid R; Salud A; Pons F; Fonseca P; Leon A; Alsina M; Visa L; Rivera F; Galan MC; Del Valle E; Vilardell F; Iglesias M; Fernandez S; Landolfi S; Cuatrecasas M; Mayorga M; Jose Paulés M; Sanz-Moncasi P; Montagut C; Garralda E; Rojo F; Hidalgo M; Lopez-Rios F
Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab
Journal of Clinical Oncology 31 4445-4445. .
-
Marquez-Medina D; Chachoua A; Martin-Marco A; Desai AM; Garcia-Reglero V; Salud-Salvia A; Muggia F
Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers?
CLINICAL & TRANSLATIONAL ONCOLOGY 15 959-964. .
-
Canal Sotelo, Jaume; Barallat Gimeno, Eva; Martin Marco, Antonio; Salud Salvia, Antonieta
Painful mouth and stomatitis due to a herpes simplex virus type 1 infection
MEDICINA PALIATIVA 20 158-159. .
-
Márquez-Medina D; Gasol-Cudós A; Taberner-Bonastre MT; Samamé Pérez-Vargas JC; Salud-Salvia A; Llombart-Cussac A
Human Papillomavirus in Non-Small-Cell Lung Cancer: The Impact of EGFR Mutations and the Response to Erlotinib
ARCHIVOS DE BRONCONEUMOLOGIA 49 79-81. .
-
Bennouna J; Sastre J; Arnold D; Österlund P; Greil R; Van Cutsem E; von Moos R; Viéitez JM; Bouché O; Borg C; Steffens CC; Alonso-Orduña V; Schlichting C; Reyes-Rivera I; Bendahmane B; André T; Kubicka S
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
LANCET ONCOLOGY 14 29-37. .
-
Muñoz A; Pericay C; García-Girón C; Alonso V; Dueñas R; Cirera L; Rivera F; Falcó E; Bustos IA; Salud A
Phase II Study of Bevacizumab, Capecitabine, and Oxaliplatin Followed by Bevacizumab Plus Erlotinib as First-Line Therapy in Metastatic Colorectal Cancer
ONCOLOGY RESEARCH 21 181-191. .
Proyectos
- Ajuts per a la contractació de personal investigador novell (FI)
- Predicción de micrometástasis en pacientes con cáncer de colon localizado de alto riesgo
- Dimerizaciones de HER2 como elemento de decición en la terapia dirigida anti-HER2 frente al cáncer de mama
- UTILITAT PRONOSTICA DELS PERFILS D'EXPRESSIO PROTEICA EN PACIENTS AMB TUMOR RESIDUAL VIABLE (>1.0 CM) DESPRES DE LA QUIMIOTERAPIA NEOADJUVANT EN CANCER DE MAMA
- Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0 cm) tras quimioterapia neoadyuvante
